Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Hypertension

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 108 articles: HTML format

Single Articles

September 2026
1. 
   Correction to: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.
   Eur Heart J. 2026 Sep 8:ehag758. doi: 10.1093.
   PubMed    
   
   
   
2. NAMAJIMA T, Ushijima R, Tanaka R
   Novel oblique dynamic chest radiography for retrocardiac pulmonary blood flow imaging in chronic thromboembolic pulmonary hypertension.
   Eur Heart J. 2026 Sep 7:ehag711. doi: 10.1093.
   PubMed    
   
   
   
3. WANG M, Liu Z, Chen Y, Wang S, et al
   Angiotensin II-driven TGF-beta1 increases platelet PAR4 expression enhancing thrombotic risk in hypertension.
   Eur Heart J. 2026 Sep 3:ehag632. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. XIE T, Ani A, Vaez A, Nolte IM, et al
   Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.
   Eur Heart J. 2026;47:4621-4637.
   PubMed     Abstract available
   
   
   August 2026
5. HEERSPINK HJL, Beernink JM, Agarwal R, Cherney DZI, et al
   Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.
   Eur Heart J. 2026 Aug 30:ehag729. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. CREA F
   Focus on heart failure: Second Universal Definition, optimal potassium levels, phenotyping of pulmonary hypertension, hereditary transthyretin amyloidosis, and the challenge of a total artificial heart.
   Eur Heart J. 2026;47:4339-4345.
   PubMed    
   
   
   
7. KROST KM, Eichner G, Fasshauer M, Eise NJ, et al
   Markers of ultra-processed food and incident arterial hypertension in the UK Biobank.
   Eur Heart J. 2026 Aug 3:ehag614. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. VAURA F, Krebs K, Kiiskinen T, Ramo J, et al
   Side effects in hypertension treatment: a pharmacogenomic analysis.
   Eur Heart J. 2026 Aug 3:ehag575. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2026
9. CHEN Z, Ge D, Li X, Wei TW, et al
   AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension.
   Eur Heart J. 2026 Jul 28:ehag568. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. MCMULLEN JR, Schnabel RB, Freedman B
    Hypertension with defective IGF1R-PI3K signalling may trigger atrial cardiomyopathy, atrial fibrillation, and stroke.
    Eur Heart J. 2026 Jul 21:ehag546. doi: 10.1093.
    PubMed    
    
    
    
11. GALLO G, Volpe M
    Weekly Journal Scan: Discontinuation due to adverse events varies across antihypertensive regimens.
    Eur Heart J. 2026 Jul 9:ehag530. doi: 10.1093.
    PubMed    
    
    
    
12. FAN Y, Chen C, Luo C, Zhou S, et al
    Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome.
    Eur Heart J. 2026 Jul 7:ehag405. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
13. NOLDE JM, Kiuchi MG, Webster M, Wilkins G, et al
    Combined hepatorenal denervation for hypertension and cardiometabolic disease: a first-in-human study.
    Eur Heart J. 2026 Jun 19:ehag460. doi: 10.1093.
    PubMed    
    
    
    
14. ETYANG AO, Guzik TJ, Perel P
    Hypertension in sub-Saharan Africa: bridging the gaps through implementation research and scientific innovation.
    Eur Heart J. 2026 Jun 5:ehag305. doi: 10.1093.
    PubMed    
    
    
    
15. GALLO G, Volpe M
    Weekly journal scan: The IMPACTS of a multidimensional approach on blood pressure control in a low-income hypertensive population.
    Eur Heart J. 2026 Jun 5:ehag421. doi: 10.1093.
    PubMed    
    
    
    May 2026
16. HASENBOHLER A, Javaux G, Payen de la Garanderie M, Szabo de Edelenyi F, et al
    Preservative food additives, hypertension, and cardiovascular diseases: the NutriNet-Sante study.
    Eur Heart J. 2026 May 20:ehag308. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. EITEL I, Saraei R, Rawish E
    Targeting hypertension with SGLT2 inhibition: the EU-funded SGLT2 HYPE trial.
    Eur Heart J. 2026 May 15:ehag301. doi: 10.1093.
    PubMed    
    
    
    April 2026
18. AN DW, Zhang DY, Staessen JA
    Single-pill combinations in the management of hypertension.
    Eur Heart J. 2026 Apr 15:ehag274. doi: 10.1093.
    PubMed    
    
    
    
19. GALLO G, Volpe M
    Weekly Journal Scan: Aldosterone synthase inhibition with baxdrostat improves 24-hour blood pressure control in patients with treatment resistant hypertension.
    Eur Heart J. 2026 Apr 8:ehag278. doi: 10.1093.
    PubMed    
    
    
    
20. CREA F
    Hypertension: diagnosis, management, and new therapeutic targets.
    Eur Heart J. 2026;47:1633-1638.
    PubMed    
    
    
    
21. SCHULTZ MG, Otahal P, Roberts-Thomson P, Stanton T, et al
    Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.
    Eur Heart J. 2026;47:1661-1671.
    PubMed     Abstract available
    
    
    
22. JUNG YH, Kim J, Han KD, Lee JY, et al
    Dementia risk across blood pressure categories: a South Korean nationwide study.
    Eur Heart J. 2026;47:1688-1698.
    PubMed     Abstract available
    
    
    
23. WU W, Liu J, Chen X, Zhu P, et al
    Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.
    Eur Heart J. 2026;47:1721-1737.
    PubMed     Abstract available
    
    
    March 2026
24. 
    Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.
    Eur Heart J. 2026 Mar 11:ehag154. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. HANSSEN H
    Hypertensive response to exercise and the theory of relativity.
    Eur Heart J. 2026 Mar 2:ehag064. doi: 10.1093.
    PubMed    
    
    
    February 2026
26. HENKIN S, Piazza G
    Improving risk assessment with right ventricular phenotyping in patients with pulmonary arterial hypertension: minimizing future surprises.
    Eur Heart J. 2026 Feb 18:ehaf1084. doi: 10.1093/eurheartj/ehaf1084.
    PubMed    
    
    
    
27. CREA F
    Focus on trials: atrial fibrillation, heart failure with reduced ejection fraction, acute coronary syndrome, ischaemic stroke, and renovascular hypertension.
    Eur Heart J. 2026;47:649-654.
    PubMed    
    
    
    
28. TADDEI S, Narkiewicz K, Bricout-Hennel S, Petrova P, et al
    Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.
    Eur Heart J. 2026 Feb 11:ehag022. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. LI XM, Yang L, Yang ZG
    Taussig-Bing heart with pulmonary hypertension in a rare adult survivor: multimodality imaging insights.
    Eur Heart J. 2026 Feb 9:ehag026. doi: 10.1093.
    PubMed    
    
    
    
30. GHIO S, Badagliacca R, D'Alto M, Acquaro M, et al
    Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.
    Eur Heart J. 2026 Feb 6:ehag023. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2026
31. ZHANG H, Guo X, Han Y
    A tale of two forces: pulmonary hypertension and hepatopulmonary syndrome in congenital portosystemic shunt.
    Eur Heart J. 2026 Jan 13:ehaf820. doi: 10.1093.
    PubMed    
    
    
    
32. SUDANO I, Parati G, Gerdts E
    Update from ESC council on hypertension.
    Eur Heart J. 2026 Jan 8:ehaf976. doi: 10.1093.
    PubMed    
    
    
    December 2025
33. BIDEL Z, Nazarzadeh M, Canoy D, McEvoy JW, et al
    Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.
    Eur Heart J. 2025 Dec 12:ehaf962. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. VERDECCHIA P, Angeli F, Reboldi G
    Should systolic pressure be lowered in isolated diastolic hypertension?
    Eur Heart J. 2025 Dec 12:ehaf950. doi: 10.1093.
    PubMed    
    
    
    
35. WANG H, Zhou H, Chai K, Yan S, et al
    Heart failure in China: a macroeconomic modelling study of intervention strategies.
    Eur Heart J. 2025 Dec 8:ehaf992. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. 
    Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by th
    Eur Heart J. 2025;46:4949.
    PubMed    
    
    
    November 2025
37. CHEN X, Jilaihawi H, Wang Y
    One-stop pulmonary artery denervation and transcatheter tricuspid annuloplasty in combined pre- and post-capillary pulmonary hypertension with severe tricuspid regurgitation.
    Eur Heart J. 2025 Nov 28:ehaf934. doi: 10.1093.
    PubMed    
    
    
    
38. LIU R, Li H
    Adherence matters-even in young adults with hypertension.
    Eur Heart J. 2025 Nov 28:ehaf913. doi: 10.1093.
    PubMed    
    
    
    
39. NIELSEN ST, Luo J, Frikke-Schmidt R
    Genetic and methodological considerations in hypertensive disorders of pregnancy and risk of cardiovascular disease.
    Eur Heart J. 2025 Nov 25:ehaf933. doi: 10.1093.
    PubMed    
    
    
    
40. YAO BY, Su YZ, Zhang LY
    Overlooked complexities in pregnancy hypertension-cardiovascular disease genetic studies.
    Eur Heart J. 2025 Nov 25:ehaf931. doi: 10.1093.
    PubMed    
    
    
    
41. KELES M, Lawrie A
    Revisiting prostaglandin biology in pulmonary arterial hypertension: targeting the EP4/ANXA2 axis.
    Eur Heart J. 2025 Nov 19:ehaf871. doi: 10.1093.
    PubMed    
    
    
    
42. GALLO G, Volpe M
    Weekly Journal Scan: Targeting aldosterone synthase in uncontrolled and resistant hypertension.
    Eur Heart J. 2025 Nov 18:ehaf892. doi: 10.1093.
    PubMed    
    
    
    
43. WHITE SJ
    HEG1: a new protein linking endothelial dysfunction and hypertension.
    Eur Heart J. 2025 Nov 11:ehaf843. doi: 10.1093.
    PubMed    
    
    
    
44. FATIMA M, Sheikh S, Ammer Z
    Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Nov 4:ehaf799. doi: 10.1093.
    PubMed    
    
    
    
45. TOKCAN M, Markwirth P, Bohm M
    Uniform benefits of empagliflozin across hypertension categories: a response.
    Eur Heart J. 2025 Nov 4:ehaf798. doi: 10.1093.
    PubMed    
    
    
    October 2025
46. PARIENTE A
    Pharmacoepidemiology as the delicate science of constructing robust plausibility where there is no certainty: the case for hypertension in young adults.
    Eur Heart J. 2025 Oct 17:ehaf712. doi: 10.1093.
    PubMed    
    
    
    
47. LI Y, Zheng J, Lu C, Fan F, et al
    Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.
    Eur Heart J. 2025 Oct 7:ehaf746. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. VOLPE M, Guzik TJ, Messerli FH
    The need for a unified categorization of hypertension across guidelines.
    Eur Heart J. 2025 Oct 3:ehaf747. doi: 10.1093.
    PubMed    
    
    
    September 2025
49. XU H, Ye L, Du C, Tang H, et al
    EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
    Eur Heart J. 2025 Sep 25:ehaf763. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. REA F, Morabito G, Corrao G, Mancia G, et al
    Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.
    Eur Heart J. 2025 Sep 25:ehaf744. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. DEWLAND TA, van Dam RM, Marcus GM
    Coffee and cardiovascular disease.
    Eur Heart J. 2025;46:3546-3554.
    PubMed     Abstract available
    
    
    
52. TAAGEBY NIELSEN S, Luo J, Tybjaerg-Hansen A, Iversen K, et al
    Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.
    Eur Heart J. 2025 Sep 3:ehaf565. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
53. AL-QAZAZI R, Emon IM, Potus F, Martin AY, et al
    Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension.
    Eur Heart J. 2025 Aug 29:ehaf611. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
54. CREA F
    Hot topics in prevention: resistant hypertension, blood pressure variability, triglycerides, and apoB-containing lipoproteins.
    Eur Heart J. 2025;46:2607-2610.
    PubMed    
    
    
    
55. GALLO G, Volpe M
    Weekly Journal Scan: BedMed cannot overcome the uncertainties on the effects of night-time antihypertensive therapy on cardiovascular outcomes.
    Eur Heart J. 2025 Jul 10:ehaf435. doi: 10.1093.
    PubMed    
    
    
    June 2025
56. CREA F
    Focus on juvenile hypertension, deep learning-qualified body composition for risk stratification, infective endocarditis, and mixed valvular heart disease.
    Eur Heart J. 2025;46:2249-2252.
    PubMed    
    
    
    
57. MENG Y, Koskinen JS, Thomson R, Juonala M, et al
    Blood pressure in childhood, young- and mid-adulthood: association with carotid plaque severity.
    Eur Heart J. 2025;46:2306-2316.
    PubMed     Abstract available
    
    
    
58. CRUMP C, Sundquist J, Sundquist K
    Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.
    Eur Heart J. 2025 Jun 23:ehaf366. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. CHASELING GK, Uchmanowicz I, Back M, Miro O, et al
    Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, E
    Eur Heart J. 2025 Jun 3:ehaf326. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
60. PROCOPI N, Zeitouni M, Kerneis M, Cayla G, et al
    Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AbetaYSS trial.
    Eur Heart J. 2025 May 22:ehaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
61. SANIDAS E, Bohm M, Oikonomopoulou I, Dinopoulou P, et al
    Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.
    Eur Heart J. 2025 Apr 25:ehaf291. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. ZHANG DY, An DW, Yu YL, Melgarejo JD, et al
    Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.
    Eur Heart J. 2025 Apr 18:ehaf220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. KOBAYASHI M, Pitt B, Ferreira JP, Rossignol P, et al
    Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.
    Eur Heart J. 2025 Apr 11:ehaf225. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. XIONG G
    Post-capillary pulmonary hypertension in heart failure: addressing statistical and methodological issues in research.
    Eur Heart J. 2025 Apr 8:ehae812. doi: 10.1093.
    PubMed    
    
    
    
65. FAUVEL C, Lamblin N
    Post-capillary Pulmonary Hypertension in Heart Failure is associated with higher mortality and morbidity risk: not just a matter of << hasard >>.
    Eur Heart J. 2025 Apr 8:ehae814. doi: 10.1093.
    PubMed    
    
    
    
66. CREA F
    Focus on blood pressure: sex-specific association with atrial fibrillation, role of gliflozins in hypertension, and new therapeutic targets in hypertension and orthostatic hypotension.
    Eur Heart J. 2025;46:1277-1280.
    PubMed    
    
    
    
67. WANG YL, Zhu H, Pan YT, Shang D, et al
    Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcbeta1/4-Stat5-NF-kappaB pathway.
    Eur Heart J. 2025;46:1335-1351.
    PubMed     Abstract available
    
    
    
68. LIN R, Fields JC, Lee R, Rosenfeld EB, et al
    Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies.
    Eur Heart J. 2025;46:1219-1228.
    PubMed     Abstract available
    
    
    March 2025
69. MESSERLI FH, Schoenenberger-Berzins R, Burnier M
    SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension.
    Eur Heart J. 2025 Mar 7:ehae751. doi: 10.1093.
    PubMed    
    
    
    
70. BOHM M, Butler J, Coats A, Lauder L, et al
    Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
71. 
    Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by th
    Eur Heart J. 2025 Feb 11:ehaf031. doi: 10.1093.
    PubMed    
    
    
    January 2025
72. MIKOLAJCZYK TP, Sliwa T, Guzik TJ
    Immunometabolic switch in hypertension: how dendritic cell mineralocorticoid receptors drive Th17 polarization and blood pressure control.
    Eur Heart J. 2025 Jan 22:ehae863. doi: 10.1093.
    PubMed    
    
    
    
73. SHARASHOVA E, Gerdts E, Ball J, Schnabel RB, et al
    Long-term pulse pressure trajectories and risk of incident atrial fibrillation: the Tromso Study.
    Eur Heart J. 2025 Jan 17:ehaf005. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
74. XIE D, Sun X, Cao Y
    Malignant pheochromocytoma associated with pulmonary hypertension.
    Eur Heart J. 2024 Dec 6:ehae842. doi: 10.1093.
    PubMed    
    
    
    
75. MIRZOYEV U
    Target 130/80: a future-focused initiative for hypertension management in Azerbaijan.
    Eur Heart J. 2024 Dec 3:ehae749. doi: 10.1093.
    PubMed    
    
    
    October 2024
76. LI Y, Gao F, Ren C, Ma G, et al
    The Netrod six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial.
    Eur Heart J. 2024 Oct 21:ehae703. doi: 10.1093.
    PubMed    
    
    
    
77. MCCARTHY CP, Touyz RM, McEvoy JW
    The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension.
    Eur Heart J. 2024 Oct 16:ehae646. doi: 10.1093.
    PubMed    
    
    
    
78. CREA F
    Focus on the European Society of Cardiology: Guidelines on hypertension, Atlas of cardiovascular disease statistics, and Consensus statement on obesity.
    Eur Heart J. 2024;45:3897-3900.
    PubMed    
    
    
    
79. KENNEDY C, Hayes P, Cicero AFG, Dobner S, et al
    Semaglutide and blood pressure: an individual patient data meta-analysis.
    Eur Heart J. 2024;45:4124-4134.
    PubMed     Abstract available
    
    
    September 2024
80. OBIEZU-UMEH C, Huffman MD, Ojji DB
    Integration of a hypertension treatment programme into Nigeria's primary healthcare system: report from a stakeholders and policymakers' workshop.
    Eur Heart J. 2024 Sep 10:ehae376. doi: 10.1093.
    PubMed    
    
    
    
81. VERGALLO R, Volpe M
    Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk.
    Eur Heart J. 2024 Sep 4:ehae531. doi: 10.1093.
    PubMed    
    
    
    
82. COHEN JB, Bress AP
    Quantifying antihypertensive effects of GLP-1 agonists.
    Eur Heart J. 2024 Sep 1:ehae520. doi: 10.1093.
    PubMed    
    
    
    August 2024
83. MCEVOY JW, McCarthy CP, Bruno RM, Brouwers S, et al
    2024 ESC Guidelines for the management of elevated blood pressure and hypertension.
    Eur Heart J. 2024 Aug 30:ehae178. doi: 10.1093.
    PubMed    
    
    
    
84. CREA F
    Expanding knowledge in atrial fibrillation, blood pressure treatment, and management of coronary and peripheral artery disease.
    Eur Heart J. 2024;45:2795-2799.
    PubMed    
    
    
    
85. BOHM M, de la Sierra A, Mahfoud F, Schwantke I, et al
    Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes.
    Eur Heart J. 2024;45:2851-2861.
    PubMed     Abstract available
    
    
    
86. MANCIA G, Facchetti R, Grassi G
    Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements.
    Eur Heart J. 2024;45:2862-2864.
    PubMed    
    
    
    
87. ROSENKRANZ S, Hoeper MM, Maron BA
    Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
    Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093.
    PubMed    
    
    
    July 2024
88. FAUVEL C, Damy T, Berthelot E, Bauer F, et al
    Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
    Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. ROGER G, Ducrocq G, Mesnier J, Sayah N, et al
    Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry.
    Eur Heart J. 2024;45:2396-2406.
    PubMed     Abstract available
    
    
    April 2024
90. VERGALLO R, Volpe M
    Lowering dietary sodium intake to reduce blood pressure: cum grano salis.
    Eur Heart J. 2024;45:1301-1302.
    PubMed    
    
    
    March 2024
91. PITRE T, Weatherald J, Humbert M
    Treatments for pulmonary arterial hypertension: navigating through a network of choices.
    Eur Heart J. 2024 Mar 5:ehae106. doi: 10.1093.
    PubMed    
    
    
    
92. MA E, Wo D, Chen J, Yan H, et al
    Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice.
    Eur Heart J. 2024;45:688-703.
    PubMed     Abstract available
    
    
    February 2024
93. MOUTCHIA J, McClelland RL, Al-Naamani N, Appleby DH, et al
    Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
    Eur Heart J. 2024 Feb 28:ehae049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. RUILOPE LM, Ortiz A, Ruiz-Hurtado G
    Hypertension and the kidney: an update.
    Eur Heart J. 2024 Feb 8:ehad896. doi: 10.1093.
    PubMed    
    
    
    January 2024
95. GUPTA A, Whiteley WN, Godec T, Rostamian S, et al
    Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
    Eur Heart J. 2024 Jan 31:ehad814. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
96. TOTH PP
    Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease.
    Eur Heart J. 2023 Dec 29:ehad797. doi: 10.1093.
    PubMed    
    
    
    
97. HE Z, Zhang D, Wang X
    Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting.
    Eur Heart J. 2023 Dec 28:ehad862. doi: 10.1093.
    PubMed    
    
    
    
98. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    PubMed    
    
    
    
99. O'DONNELL M, Yusuf S, Vogt L, Mente A, et al
    Potassium intake: the Cinderella electrolyte.
    Eur Heart J. 2023;44:4925-4934.
    PubMed     Abstract available
    
    
    
100. SCHNEIDER SR, Muller J, Bauer M, Mayer L, et al
     Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy.
     Eur Heart J. 2023 Dec 11:ehad789. doi: 10.1093.
     PubMed    
     
     
     November 2023
101. VOLPE M, Galiuto L
     More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostat.
     Eur Heart J. 2023 Nov 9:ehad756. doi: 10.1093.
     PubMed    
     
     
     
102. TSCHIDERER L, van der Schouw YT, Burgess S, Bloemenkamp KW, et al
     Hypertensive disorders of pregnancy and cardiovascular disease risk: A Mendelian Randomisation study.
     Eur Heart J. 2023;44.
     PubMed     Abstract available
     
     
     
103. GALIE N, Palazzini M, Manes A
     Confirmation of survival prediction based on 2022 ESC/ERS pulmonary hypertension guidelines new haemodynamic thresholds.
     Eur Heart J. 2023 Nov 7:ehad672. doi: 10.1093.
     PubMed    
     
     
     
104. ACKLAND GL, Patel A, Abbott TEF, Begum S, et al
     Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial.
     Eur Heart J. 2023 Nov 7:ehad716. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2023
105. BRAUNWALD E
     Inhibition of angiotensinogen in the treatment of hypertension.
     Eur Heart J. 2023 Oct 27:ehad704. doi: 10.1093.
     PubMed    
     
     
     September 2023
106. LIU JN, Zhao ZG, Luo FM
     Pulmonary hypertension-related dynamic left ventricular outflow tract obstruction.
     Eur Heart J. 2023 Sep 19:ehad605. doi: 10.1093.
     PubMed    
     
     
     
107. LIUZZO G, Volpe M
     Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges.
     Eur Heart J. 2023 Sep 8:ehad593. doi: 10.1093.
     PubMed    
     
     
     August 2023
108. RAO S, Nazarzadeh M, Canoy D, Li Y, et al
     Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality.
     Eur Heart J. 2023 Aug 23:ehad535. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum